G1 Therapeutics Provides First Quarter 2022 Financial Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
G1 Therapeutics (GTHX) PT Lowered to $42 at Needham & Company
May 4, 2022 3:51 PM EDTNeedham & Company analyst Gil Blum lowered the price target on G1 Therapeutics (NASDAQ: GTHX) to $42.00 (from $44.00) while maintaining a Buy rating following earnings.
The analyst commented, "G1 reported COSELA sales of $5.5M, ~24% q/q increase. G1's internal sales team was... More
